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HER-2isanimportantoncoproteinoverexpressedinabout15–25%ofbreastcancers.Wehypothesizedthattheabilityofcurcumin
to downregulate HER-2 oncoprotein and inhibit the signal transduction pathway of PI3K/Akt, MAPK, and NF-κBa c t i v a t i o nm a y
be important in the treatment of HER-2-overexpressed breast cancer. To examine the eﬀect of curcumin on breast cancer cells,
MCF-7,MDA-MB-231,MCF-10A,BT-474,andSK-BR-3-hr(aherceptinresistantstrainfromSK-BR-3)cellswereusedfor invitro
analysis. The in vivo eﬀect of curcumin on HER-2-overexpressed breast cancer was investigated with the HER-2-overexpressed BT-
474 xenograft model. Cell growth, cell cycle change, the antimobility eﬀect, signal transduction, and xenograft volume analysis
between groups treated with herceptin and/or curcumin were tested. Curcumin decreased the cell growth of various breast cancer
cell lines (MCF-7, MDA-MB-231, MCF-10A, BT-474, and SK-BR-3-hr). In Western blot analysis, the phosphorylation of Akt,
MAPK, and expression of NF-κB were reduced in BT-474 cells, but not in SK-BR-3-hr cells, after treatment with herceptin. When
treated with curcumin, the HER-2 oncoprotein, phosphorylation of Akt, MAPK and expression of NF-κB were decreased in both
BT-474 and SK-BR-3-hr cells. In the BT-474 xenograft model, though not as much as herceptin, curcumin did eﬀectively decrease
the tumor size. The combination of curcumin with herceptin was not better than herceptin alone; however, the combination
of taxol and curcumin had an antitumor eﬀect comparable with taxol and herceptin. The results suggested that curcumin has
potential as a treatment for HER-2-overexpressed breast cancer.
1.Introduction
Around 15–25% of breast cancers are noted to overexpress
the human epithelial growth factor receptor 2 (HER-2) [1–
3], patients with HER-2 overexpression were associated with
a poor prognosis, more disease relapse, and distant metas-
tasis [3–6]. Herceptin (generic name: Trastuzumab), which
eﬀectively inhibits the HER-2-related PI3k/Akt and MAPK
pathways, is the ﬁrst targeted therapeutic agent developed
and approved for the treatment of patients with HER-2-
overexpressed breast cancer [7–12]. Despite the success of
herceptin, a signiﬁcant proportion of HER-2-positive breast
cancer patients responded poorly to the treatment [13, 14].
In addition, some patients that initially responded to the
therapy became resistant within one year [14, 15]. The
refractory state of these HER-2-positive breast carcinomas2 Evidence-Based Complementary and Alternative Medicine
illustrates the need to examine the mechanisms underlying
tumor resistance and the necessity to seek novel treatment
strategies.
Curcumin (diferuloylmethane) is a yellow pigment de-
rived from the rhizome of the plant Curcuma longa L.
The powdered rhizome of this plant, called turmeric, is
commonly used in the preparation of curries. Curcumin,
as a polyphenol with a diarylheptanoid structure containing
two α, β-unsaturated ketones, is considered to be the major
active constituent of turmeric [16, 17]. In addition to its
wide range of pharmacological activities, the anticancer
properties of curcumin have attracted great interest [18–20].
The ability of curcumin to downregulate EGFR [19, 21, 22]
and HER-2 [23] oncoproteins and aﬀect the PI3K/Akt [24]
and MAPK [25] pathways, with which herceptin interfered,
raised interest in the potential utility of curcumin in the
treatment of HER-2-positive breast cancer.
Taxol (generic name: Paclitaxel) combined with her-
ceptin is one of the current preferred regimens for the
treatment of HER-2-overexpressed breast cancer [11, 26].
NF-κB is an important factor related to proliferation and
antiapoptosis [27, 28], and the activation of NF-κBp l a y s
an important role in the chemoresistance of taxol [29, 30].
Curcumin has the well-known ability to downregulate NF-
κB[ 31, 32]. The combination of curcumin with taxol could
suppress taxol-related NF-κB activation and enhance the
antitumor eﬀect of taxol [31, 33]. The evolving concept
of combining a monoclonal antibody (herceptin or per-
tuzumab) for the extracellular domain of HER-2 and small
molecule tyrosine kinase inhibitors (TKI) for EGFR (geﬁ-
tinib,erlotinib)[34–36]orEGFR/HER-2(lapatinib)[37]has
shown beneﬁt in some preclinical studies and patient trials.
The multifunctions of curcumin in downregulating EGFR
and HER-2 oncoproteins, reducing the phosphorylation of
Akt and MAPK and suppressing NF-κB activation, led to
interest in using curcumin in the treatment of HER-2-
overexpressed breast cancer, along with herceptin and/or
taxol.
The aim of this preclinical study was to explore the
potential application of curcumin in the treatment of HER-
2-overexpressedbreastcancerandexaminetheinteractionof
curcumin and herceptin, which has rarely been reported.
2.MaterialsandMethods
2.1. Cell Culture and Reagents. To examine the eﬀect of
herceptin and curcumin on breast cancer cell lines with
various estrogen receptors (ER) and HER-2 receptors, MCF-
7 [ER(+), HER-2(−)], SK-BR-3-hr (a herceptin-resistant
strain from SK-BR-3 breast cancer cells) [ER(−), HER-
2(+)], BT-474 [ER(+), HER-2(+)], MDA-MB-231 [ER(−),
HER-2(−)], and normal breast epithelial cells, MCF-10A
[ER(−), HER-2(−)], were chosen. The expression of HER-
2 oncoprotein in MCF-7, MCF-10A, MDA-MB-231, BT-
474, and SK-BR-3-hr cells was veriﬁed by western blotting
(Figure 1).
The cell lines (MCF-7, BT-474, MDA-MB-231, and
normal breast MCF-10A) used in this study were purchased
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Figure 1: The expression of HER-2 oncoprotein in various human
breastcancercelllines.Cellswerelysedandanalyzedbywesternblot
as described in methods. As revealed in ﬁgure, BT-474 and SKBr-3-
hr were HER-2-overexpressed breast cancer cell lines. Whiles MCF-
7, MCF-10A, and MDA-MB-231 cells were HER-2-unexpressed
breast cancer cells.
from American Type Culture Collection (ATCC). SK-BR-
3-hr, a herceptin-resistant strain, was a kind gift from
Dr. L.-M. Tseng. The resistance of herceptin was induced
by repeated culture of herceptin-treated SK-BR-3 cells,
which were herceptin-sensitive and purchased from ATCC.
The MCF-7 cell line was maintained in RPMI medium
with 10% fetal bovine serum, 50unit/mL penicillin, and
50unit/mL streptomycin. The MDA-MB-231 cells were
cultured in L15 medium containing 10% fetal bovine serum,
50unit/mL penicillin, and 50unit/mL streptomycin. BT-474
cellsweremaintainedinDMEM/F12mediumwith10%fetal
bovine serum, 50unit/mL penicillin, and 50unit/mL strep-
tomycin. SK-BR-3-hr cells were maintained in DMEM/F12
medium with 10% fetal bovine serum, 50unit/mL peni-
cillin, and 50unit/mL streptomycin. MCF-10A was main-
tained in MEBM medium with 1% penicillin-streptomycin,
50μg/mL hydrocortisone, 1μg/mL EGF, 500μg/mL insulin,
and 10μg/mL cholera toxin. Cells were maintained at 37◦C
in a humidiﬁed atmosphere in the presence of 5% CO2.
2.2. Compounds. Curcumin (Sigma-Aldrich, Inc., St. Louis,
Mo, USA) was dissolved in DMSO at 50μg/mL as a stock
solution.HerceptinwaspurchasedfromRocheanddissolved
in PBS at 50μg/mL as stock. Taxol was dissolved in 49.7%
ethanol at 6mg/mL as stock.
2.3. Growth and Cell Proliferation Analysis. Cell proliferation
was measured using sulforhodamine B (SRB) colorimetric
analysis, which is used for cell density determination, based
on the measurement of cellular protein content [38]. The
method described here has been optimized for the toxicity
screening of compounds to adherent cells in a 96-well
format. After an incubation period, cell monolayers were
ﬁxed with 10% (wt/vol) trichloroacetic acid and stained with
SRB for 30min after which the excess dye was removed
by washing repeatedly with 1% (vol/vol) acetic acid. The
protein-bounddyewasdissolvedin10mMTrisbasesolutionEvidence-Based Complementary and Alternative Medicine 3
for OD determination at 510nm using a microplate reader.
The results were linear over a 20-fold range of cell numbers.
The trypan blue exclusion test was also used to conﬁrm
the cell proliferation result in herceptin- and curcumin-
treated BT-474 and SK-BR-3-hr cells. Cells were stained with
4% trypan blue (Sigma), and viable cells counted with a
hemocytometer under a light microscope.
2.4. Determination of Combinatorial Eﬀects. The ability of
herceptin and curcumin to act in a synergistic, additive, or
antagonistic matter with regard to growth inhibition was
determined by a combination index (CI) as proposed by
Chou and Talalay [39, 40]. The Calcusyn software (Biosoft,
Great Shelford, Cambridge, UK) was used to determine the
CI for each concentration of drug mixture used. A CI value
<1 represented a case where synergism of herceptin and
curcumin was present. CI values of 1 and >1r e p r e s e n t e d
additive and antagonistic eﬀects, respectively.
2.5. Cell Cycle Analysis. Breast cancer cells were plated at a
density of 5 × 105/dish in 60 × 15-mm culture dishes and
allowed to adhere overnight. Cells were then incubated with
media containing herceptin and/or curcumin at diﬀerent
concentrations as indicated. Following 72 hours (h) of
incubation, the cells were washed with PBS, trypsinized, and
collectedbycentrifugationat1,500rpmfor10minutes.After
centrifugation, the supernatant was removed, and the cell
p e l l e t sw e r eﬁ x e dw i t h7 5 %a l c o h o la t−20◦C.A f t e r1ho f
incubation, the cell pellets were collected by centrifugation
at 1,500rpm for 10 minutes. The pellets were incubated with
propidium iodide (PI) solution (10μg/mL) for 30 minutes.
The cell cycle phase was determined by Cytomics FC500 ﬂow
cytometry (Beckman Coulter).
2.6. Mobility Test. Cell migration is necessary in many
physiological processes, such as wound healing, and is a
characteristic of cancer cell metastasis [41]. The inhibitory
eﬀect of herceptin and/or curcumin on diﬀerent breast
cancer cell lines was tested by wound healing assay. Upon
inﬂicting a scratch wound, these cells were treated with
various concentrations of curcumin and/or herceptin for 4h
and returned to standard media in an attempt to minimize
any cytotoxic eﬀects that could potentially confound our
observations. Following 20h of further incubation, the areas
of the wounds were measured using Image J software
(http://rsb.info.nih.gov/ij/).
2.7. Western Blot Analysis. Breast cancer cells were allowed
to incubate with curcumin and/or herceptin at various
concentrations and time points as indicated and harvested
after treatment. Whole cell lysate was prepared by resus-
pending the cells in RIPA buﬀer supplemented with protease
inhibitors cocktail (PIERCE) and incubating the cells on ice
for 30 minutes. Cell lysates were centrifuged at 13,000 xg
for 10 minutes and the supernatant collected. The protein
concentration was measured using the Bradford assay (Bio-
Rad Laboratories, Hercules, Calif, USA).
An aliquot of protein lysate (10μg) from each sample
was mixed with 2X Laemmli sample buﬀer (Bio-Rad,
Hercules, Calif, USA), and the protein lysate was separated
in 10% SDS-polyacrylamide gels for 1h. After transferring
the sample to a nitrocellulose membrane, the membrane
was blocked with 5% milk in 1X TBST buﬀer (10mM
Tris, 150mM NaCl, 0.5% Tween-20, pH 7.4) for 1h at
room temperature and immunoblotted using the following
antibodies: HER-2, phosphorylated Akt (p-Akt), total Akt,
phosphorylated MAPK (p-MAPK), total MAPK, and NF-κB
(Cell Signaling Technology). The proteins were probed with
anti-HER-2 (Cell Signaling Technology), anti-p-Akt, anti-
total Akt, anti-p-ERK1/2, anti-ERK 1/2, anti-NF-κB, and
anti-β-actin (Sigma) at 4◦C overnight, followed by incuba-
tionwithhorseradishperoxidase-conjugatedsecondaryanti-
bodies (Sigma). Protein visualization was performed using
the enhanced chemiluminescence kit (PIERCE) according to
themanufacturerprotocol.Equalloadingoftotalproteinwas
normalized with the β-actin signal.
2.8. In Vivo Model: Xenograft of HER-2-Overexpressed Breast
Cancer in Nude Mice. HER-2-overexpressed BT-474 cells
(1 × 107 cells per mice) were injected into 4- to 6-week-
old female, athymic nude mice subcutaneously (s.c.) in the
right ﬂank region to form xenografts. Prior to tumor cell
inoculation, all mice were primed with 17β-estradiol pellets
introduced subcutaneously in a biodegradable carrier binder
7 days before inoculation of the tumor (1.7mg of estradiol
per pellet, Innovative Research of America, Inc.) to promote
tumor growth. Then, 1 × 107 BT-474 cells, suspended in
(200μL) growth-factor-reduced matrigel (BD Bioscience,
Bedford, MA), were injected s.c. into the right ﬂank region.
Ap e r i o do f1 4t o2 1d a y se l a p s e dt oa l l o wf o r m a t i o n
of tumor nodules. Tumor nodules were monitored twice
weekly by a single observer using serial micrometer (mm)
measurements, with tumor volume calculated as the product
of length × width2/2. Six animals were randomly assigned
to each treatment group. Statistical tests were performed to
assureuniformityinstartingvolumesbetweentreatmentand
control groups at the beginning of each experiment.
Treatment groups included the control, herceptin alone,
curcumin alone, and the combination of herceptin and
curcumin. To evaluate the eﬀect of curcumin and/or her-
ceptin with chemotherapeutic agents, taxol alone, taxol and
herceptin, taxol and curcumin, and taxol + herceptin +
curcumin regimens were tested. Treatment with diﬀerent
protocols was initiated 21–28 days postxenograft inoculation
status, at which time the xenograft volume was measured
at around 50–100mm3.D i ﬀerences in xenograft volume on
the 28th posttreatment day between groups were analyzed by
single-factor analysis of variance (ANOVA). The treatment
protocol is summarized.
(a) Controlgroup:sterile0.1%DMSOintra-peritoneally
(i.p.)injectiononceperweekfor4consecutiveweeks.
(b) Herceptin-only group: loading dose of 4mg/kg her-
ceptin in sterile PBS, administered by i.p. injection,
then a dose of 2mg/kg maintained at once per week,
for 4 consecutive weeks.4 Evidence-Based Complementary and Alternative Medicine
(c) Curcumin only: curcumin dissolved in 0.1% DMSO
injected i.p. at a dose of 45mg/kg twice per week for
4 consecutive weeks.
(d) Combined curcumin and herceptin: curcumin dis-
solved in 0.1% DMSO injected i.p. at a dose of
45mg/kg twice per week, combined with a loading
dose of 4mg/kg herceptin in sterile PBS, admin-
istered by i.p. injection, then a dose of herceptin
2mg/kg maintained at once per week, for 4 consec-
utive weeks.
(e) Taxol-alone group: taxol 10mg/kg i.p. once per week
for 4 consecutive weeks.
(f) Taxol + herceptin: taxol 10mg/kg i.p. once per week,
combinedwithaloadingdoseof4mg/kgherceptinin
sterilePBS,administeredbyi.p.injection,thenadose
of herceptin 2mg/kg maintained at once per week,
for 4 consecutive weeks.
(g) Taxol and curcumin: taxol 10mg/kg i.p. once per
week, curcumin dissolved in DMSO injected i.p. at
a dose of 45mg/kg twice per week for 4 consecutive
weeks.
(h) Taxol, curcumin, and herceptin: taxol 10mg/kg i.p.
once per week, curcumin dissolved in 0.1% DMSO
injected i.p. at a dose of 45mg/kg twice per week,
combinedwithaloadingdoseof4mg/kgherceptinin
sterilePBS,administeredbyi.p.injection,thenadose
of herceptin maintained at 2mg/kg once per week,
for 4 consecutive weeks.
After completing 4 weeks of treatment, the mice were
sacriﬁced before recording body weight and tumor volume.
The tumor was harvested and processed for various ana-
l y t i c a lp u r p o s e s .T h ea n i m a lu s ep r o t o c o lw e r er e v i e w e d
and approved by the Institutional Animal Care and Use
Committee of Changhua Christian Hospital, Changhua,
Taiwan.
2.9. Statistical Analysis. Analyses were performed using the
Statistical Analysis System (SAS 9.1). Data are presented
as mean ± standard deviation, except where indicated.
Comparisons between groups were analyzed using the chi-
square test, Student’s two-tailed t-test, or one-way ANOVA
with Bonferroni’s correction, as appropriate. A value of P<
0.05 is considered statistically signiﬁcant.
3. Results
3.1. Eﬀects of Herceptin or Curcumin on Cell Proliferation.
To examine the biological eﬀect of herceptin and curcumin,
breast cancer cell lines were treated with diﬀerent con-
centrations of herceptin (0.1–10μg/mL) or curcumin (1–
25μg/mL) for 72h. Cell proliferation change was assayed
with an SRB assay. As shown in Figure 2(a), in HER-2-
overexpressed BT-474 breast cancer cells, cell proliferation
was inhibited by herceptin in a dose-dependent manner.
Cell proliferation decreased to 60% after treatment with
1μg/mL of herceptin and reached a plateau when with
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Figure 2: The eﬀect of herceptin and curcumin on growth of
diﬀerent breast cancer cell lines. Cells were incubated with diﬀerent
levelsofherceptin(a)orcurcumin(b)for72h,respectively,andcell
growth was measured using SRB assay.
a concentration >1μg/mL. In SK-BR-3-hr breast cancer
cells, an HER-2-overexpressed and herceptin-resistant breast
cancer cell line, cell growth was not inhibited by herceptin,
even at a 10μg/mL high concentration. The growth of MCF-
7 and MCF-10A, which were non-HER-2-overexpressed
cells, was not aﬀected by herceptin treatment. The growth
of MDA-MB-231 cells decreased to 64% of the control after
10μg/mL of herceptin treatment (Figure 2(a)).
In examining the eﬀect of curcumin treatment on these
celllines,wefoundthatthecellproliferationsoftheseﬁvecell
lines (MCF-7, BT-474, SK-BR-3-hr, MCF-10A, and MDA-
MB-231) were all decreased after treatment with curcumin,
with diﬀerent sensitivities (Figure 2(b)). The SK-BR-3-hr,
MCF-10A, and MDA-MB-231 cells were more sensitive to
curcumin than BT-474 and MCF-7 cells. After treatmentEvidence-Based Complementary and Alternative Medicine 5
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Figure 3: Cell growth of HER-2-overexpressed breast cancer cells with combined treatment of herceptin and curcumin. (a) The combined
eﬀectsofherceptinandcurcuminonthegrowthofBT-474andSK-BR-3-hrcells.CellgrowthwasanalyzedbySRBassayafterdrugtreatment
for 72h. (b) The combinational eﬀects of herceptin and curcumin on BT-474 and SK-BR-3-hr cells were analyzed by trypan blue exclusion
assay after drug treatment for 72h.
with 10μg/mL of curcumin, the cell proliferation of HER-
2-overexpressed BT-474 cells and herceptin-resistant SK-BR-
3-hr cells decreased to 65% and 20%, respectively.
3.2. Combination Treatment of Cells with Herceptin and
Curcumin. Figure 3(a) shows the proliferation of diﬀerent
cell lines after treatment with a combination of herceptin
and curcumin. In the HER-2-overexpressed BT-474 cells,
we found that the antiproliferative eﬀect of herceptin was
not aﬀected by the addition of curcumin. Curcumin could
further decrease the proliferation of BT-474 cells when
combined with herceptin. No apparent synergistic eﬀect was
presented when herceptin was combined with curcumin in
the SK-BR-3-hr cells. The antiproliferative eﬀect was mainly
from curcumin, and the combination of herceptin with
curcumin did not reveal a more antiproliferative eﬀect than
curcumin alone.
Trypan blue exclusion assay conﬁrmed that both her-
ceptin and curcumin inhibited the BT-474 cells dose-
dependently. The combination of herceptin and curcumin
further eﬀectively decreased the cell viability of BT-474
cells (Figure 3(b)). The SK-BR-3-hr cells that we used here
were resistant to herceptin but sensitive to curcumin. The
combinationofherceptinandcurcumineﬀectivelydecreased6 Evidence-Based Complementary and Alternative Medicine
Table 1: The combination index of herceptin and curcumin treatment of the growth of BT-474 cells.
Herceptin (μg/mL) Curcumin (μg/mL) Fa CI Eﬀect
0.1 5 0.34 0.669 Synergistic
0.1 10 0.45 0.836 Synergistic
0.1 15 0.54 0.900 Synergistic
1 5 0.52 0.393 Synergistic
1 10 0.52 0.713 Synergistic
1 15 0.54 0.953 Synergistic
2 5 0.52 0.467 Synergistic
2 10 0.53 0.750 Synergistic
2 15 0.54 1.013 Additive
5 5 0.5 0.794 Synergistic
5 10 0.52 1.007 Additive
5 15 0.56 1.075 Additive
10 5 0.49 1.354 Antagonistic
10 10 0.54 1.195 Antagonistic
10 15 0.57 1.241 Antagonistic
Av a l u eo fC I<1 represents a case where synergism of herceptin and curcumin was present. CI values of 1 and >1 represent additive and antagonistic eﬀects,
respectively. Fa, fraction aﬀected; CI, combination index.
the cell viability of SK-BR-3-hr cells. However, no apparent
synergistic or antagonistic eﬀect was present in SK-BR-3-hr
cells when a combination of herceptin and curcumin was
used.
Thecombinationeﬀectofherceptinandcurcuminonthe
growth of BT-474 breast cancer cells was further analyzed
with Calcusyn software for calculation of the CI. The
combination of herceptin with curcumin exerted a biphasic
interaction in BT-474 cells. The CI was less than 1 and
showed a synergistic eﬀect in the following conditions: a
l o wd o s eo fh e r c e p t i n( 0 . 1 – 1 μg/mL) with curcumin (5–
15μg/mL), 2μg/mL herceptin with curcumin (5–10μg/mL),
or 5μg/mL herceptin with curcumin 5μg/mL. The CI was
larger than 1 and showed an antagonistic eﬀect when using
a high dose of herceptin (>10μg/mL) with curcumin (5–
15μg/mL). The CI and interaction between herceptin and
curcumin in BT-474 cells are summarized in Table 1.
3.3. Eﬀect of Herceptin and/or Curcumin on HER-2-Related
Akt and MAPK Pathways in BT-474 and SK-BR-3-hr Cells.
In the HER-2-overexpressed BT-474 and SK-BR-3-hr cells,
phosphorylation of Akt and MAPK was observed (Figure 4).
Herceptin dose-dependently inhibited the phosphorylation
of Akt and MAPK in BT-474 breast cancer cells (left
panel, Figure 4(a)). HER-2 oncoprotein was not depleted by
herceptintreatment,evenathighconcentrations(10μg/mL).
The addition of herceptin on SK-BR-3-hr cells did not
decrease the expression of HER-2 oncoprotein nor decrease
the phosphorylation of Akt and MAPK, even at a 10μg/mL
concentration (right panel, Figure 4(a)). This was compati-
ble with the fact that this SK-BR-3-hr cell line was a strain
resistant to herceptin. When treated with curcumin, the
phosphorylationofAktandMAPKwasdecreased,combined
with the downregulation of HER-2 oncoprotein, in a dose-
dependent manner in both the BT-474 and SK-BR-3-hr cells
(Figure 4(b)).
The level of NF-κB in BT-474 cells was decreased along
with the decreased phosphorylation of Akt and MAPK after
treatment with herceptin. The level of NF-κB was increased,
even in high concentrations of herceptin-treated SK-BR-3-
hr cells. When treated with curcumin, the level of NF-κB
was decreased in a dose-dependent manner in both BT-474
and SK-BR-3-hr cells. The combination of herceptin and
curcumin treatment resulted in a decreased level of HER-2
oncoprotein, p-Akt, p-MAPK, and NF-κB in both BT-474
and SK-BR-3-hr cells (Figure 4(c)).
3.4. Eﬀect of Curcumin and/or Herceptin on BT-474 Breast
Cancer Cell Cycle. To further characterize the eﬀects of
curcumin and/or herceptin on breast cancer cell growth,
analyses of cell cycle phase distribution were conducted. The
cell cycle of BT-474 cells without drug treatment showed a
G0/G1 phase of 74%, S phase of 19%, and G2/M phase of
7%.Whentreatedwithherceptin,theG0/G1phaseincreased
from 74% to 79%, the S phase decreased from 19% to 11%,
and the G2/M phase increased from 7% to 10%. When
BT-474 cells were treated with curcumin, the G0/G1 phase
remained at 74%, the S phase decreased from 19% to 9%,
and G2/M increased from 7% to 20%. The combination
of 1μg/mL of herceptin with 10μg/mL curcumin showed
a decrease in the S phase (from 19% to 12%) without an
apparentchangeintheG0/G1(from74%to78%)andG2/M
phases (7% to 10%). The results indicated that no signiﬁcant
change in cell cycle progression was observed in BT-474 cells
after treatment with herceptin and/or curcumin.
In SK-BR-3-hr cells, the cell cycle was not changed
after treatment with herceptin, which is compatible withEvidence-Based Complementary and Alternative Medicine 7
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Figure 4: The level of HER-2, phosphorylated Akt, MAPK, and NF-κB after treatment with herceptin and/or curcumin in HER-2-
overexpressed breast cancer cells. The dosage eﬀects of herceptin (a), curcumin (b), and the combination of herceptin and curcumin (c)
on the BT-474 and SK-BR-3-hr cells, respectively. The number at the bottom of each lane indicates the relative fold change of control.
the resistance of this cell line. When treated with curcumin
for 48h, the cell cycle of SK-BR-3-hr showed a decrease in
the G1 phase (65% to 37%) and an increase in the S phase
(28% to 37%) and G2/M phase (6% to 25%). Compared
with the control, the combination of 1μg/mL herceptin and
10μg/mL curcumin showed a decrease in the G1 (65% to
53%), no apparent change in the S phase (28% to 27%), and
an increase in the G2/M phase (6% to 19%).
3.5. Eﬀect of Curcumin and/or Herceptin on the Mobility of
Diﬀerent Breast Cancer Cells. The inhibitory eﬀect of her-
ceptin and/or curcumin on diﬀerent breast cancer cell lines
was tested by wound-healing assay. Curcumin showed an
apparent antimobility eﬀect as illustrated in the MCF-7,
MDA-MB-231, and SK-BR-3-hr cells (Figure 5). No eﬀect
of herceptin and/or curcumin on the mobility of BT-474
cells was observed due to the lack of migration of these
cells. In the SK-BR-3-hr cells, cell migration persisted despite
treatment with herceptin, which is consistent with herceptin
resistance. When treated with curcumin, cell migration was
greatlyinhibited ascomparedwiththecontrol,revealingthat
curcumin had an apparent antimobility eﬀect on SK-BR-3-
hr cells. The combination of herceptin and curcumin did
not have a better antimobility eﬀect than curcumin alone.
In the wound healing assay, curcumin showed an apparent
antimobility eﬀect in MCF-7, SK-BR-3-hr, and MBA-MB-
231 breast cancer cells.
3.6. Curcumin and/or Herceptin Inhibited Tumor Growth
in the Xenograft Animal Model. Compared with the con-
trol group, the mice treated with curcumin, herceptin,
or combined herceptin and curcumin all had a smaller
mean xenograft tumor volume after 4 weeks of treatment
(control group 273.6 ± 190.1mm3, curcumin group 63.6 ±
25.7mm3, herceptin group 36.3 ± 7.8mm3, and combined
herceptin and curcumin group 34.1 ± 25.0mm3, P = 0.001)8 Evidence-Based Complementary and Alternative Medicine
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Figure 5: Changes in mobility of MCF-7, MDA-MB-231, and SK-BR-3-hr cells after treatment with herceptin and/or curcumin. The
antimobility eﬀect of herceptin and/or curcumin on breast cancer cells were tested by a wound-healing assay. The anti-mobility eﬀect was
illustrated in the MCF-7, MDA-MB-231 and SK-BR-3-hr cells, respectively. ∗P<0.05; ∗∗P<0.01; ∗∗∗P<0.001.
(Figure 6(a)). The curcumin alone group had a larger mean
xenograft tumor size than the herceptin-alone group (63.6 ±
25.7mm3 versus 36.3 ± 7.8mm3, P = 0.003). The combined
herceptin and curcumin group showed a smaller mean tu-
mor volume than the curcumin-alone group (34.1 ± 25.0
versus 63.6 ± 25.7mm3, P = 0.079) or herceptin-alone
group (34.1 ± 25.0 versus 36.3 ± 7.8mm3, P = 0.324),
although without statistical signiﬁcance.
The eﬀect of combining curcumin and/or herceptin
with taxol was tested by comparing the eﬀects of taxol,
taxol + herceptin, taxol + curcumin, and taxol + herceptin
+ curcumin regimens in the BT-474 xenograft model. In
another set of experiments, 24 mice inoculated with 1 ×
107 BT-474 cells were randomized into 4 groups and treated
with taxol, taxol + herceptin, taxol + curcumin, or combined
taxol+herceptin+curcumin.After4weeksoftreatment,the
mean xenograft tumor volumes were taxol 58.3 ± 11.2mm3,
t a x o l+h e r c e p t i n3 5 . 0± 13.4mm3, taxol + curcumin 44.5
± 6.2mm3, and combined taxol + herceptin + curcumin
group 31.3 ± 27.7mm3.T h ea n t i t u m o re ﬀect of taxol +
herceptin was apparent, and combined taxol and curcumin
had a comparable antitumor eﬀect (44.5 ± 6.2 versusEvidence-Based Complementary and Alternative Medicine 9
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Figure 6: In vivo eﬀects of curcumin on the herceptin and/or taxol-treated HER-2-overexpressed breast cancer xenografts. The HER-2-
overexpressed BT-474 cells were injected in 4–6-week-old, female, athymic, nude mice subcutaneously at 1 × 107 cells/tumor in the right
ﬂank region to form xenografts. Six mice per group were treated with diﬀerent protocols with tumor volume monitored biweekly for
consecutive4weeks.(a)Themeanxenografttumorvolumechangeofcontrol(0.1%DMSO),herceptin,curcumin,andcombinedcurcumin
and herceptin. (b) The mean xenograft tumor volume of taxol, taxol + herceptin, taxol + curcumin, and combined taxol + herceptin +
curcumin. (c) The body weight change of these mice treated with herceptin and/or curcumin. DMSO, dimethyl sulfoxide.
35.0 ± 13.4mm3, P = 0.884). The combination of taxol,
herceptin, and curcumin resulted in the smallest tumor
volume, but this was not statistically diﬀerent from that of
the taxol and herceptin regimen (31.3 ± 27.7 versus 35.0
± 13.4mm3, P = 0.079) (Figure 6(b)). The body weight of
these mice treated with herceptin and/or curcumin was quite
stable during the 4-week period (Figure 6(c)).
4. Discussion
This study was designed to test the eﬃcacy of curcumin
in HER-2-overexpressed breast cancer, with a direct com-
parison with herceptin in the in vitro cell line and in vivo
xenograft animal model. Our preclinical result revealed that
curcumin reduced the cell viability of diﬀerent breast cancer
cell lines, including MCF-7 (ER-positive, HER-2-negative),
MDA-MB-231 (ER-negative, HER-2-negative), HER-2-over-
expressed BT-474 (ER-positive, HER-2-positive), and her-
ceptin-resistant SK-BR-3-hr (ER-negative, HER-2-positive)
cells. The level of HER-2 oncoprotein, p-Akt, p-MAPK,
and NF-κB were decreased in a dose- and time-dependant
manner in BT-474 and SK-BR-3-hr cells when treated with
curcumin. The cell cycle perturbation by curcumin was
mainly found in the increase in the G2/M phase. The
apparent antimobility eﬀect of curcumin was also revealed
in the MCF-7, MDA-MB-231, and SK-BR-3-hr cells. The
combinational eﬀect of herceptin with curcumin was a
biphasic interaction on the growth of BT-474 cells. When
a low dose of herceptin was used with curcumin, there was
a synergistic eﬀect, but an antagonistic eﬀect was observed
when a high dose of herceptin was used. In the BT-474
xenograft model, curcumin treatment eﬀectively decreased10 Evidence-Based Complementary and Alternative Medicine
the tumor size, and the combination of taxol with curcumin
had an antitumor eﬀect comparable with that of taxol and
herceptin treatment.
The action of herceptin in inhibiting ErbB2 (HER-
2) signaling involves the reduced phosphorylation of Akt
but not endocytic downregulation of ErbB2 [42]. HER-2
oncoprotein was not depleted by herceptin, even at a high
concentration (Figure 4). The exact mechanism of herceptin
resistance is not clear, and possible mechanisms include
obstacles to herceptin-binding to HER-2, upregulation of
HER-2 downstream signaling pathways, signaling through
alternative pathways, or failure to trigger immune-mediated
mechanisms to destroy tumor cells [14]. In the herceptin-
resistant SK-BR-3-hr cells, the persistent activation of
PI3K/Akt and MAPK pathways, despite treatment with
herceptin,mayhavebeenacquiredthroughrepeatedcultures
of herceptin-treated SK-BR-3 cells.
NF-κBactivationplayedanimportantroleinchemother-
apy resistance [29, 30], and targeting NF-κB showed im-
proved beneﬁts in some preclinical HER-2-overexpressed
cancer cells [28, 43]. In HER-2-overexpressed breast cancer,
ErbB2 activates NF-κB via signaling that includes PI3K,
PDK1, Akt, protein kinase 2 (CK2), and CKBBP1 [44]. In
herceptin-sensitive HER-2-overexpressed BT-474 cell lines,
herceptin treatment eﬀectively decreased the phosphoryla-
tion of Akt, MAPK and the expression of NF-κB( Figure 4).
Whether the resistance to herceptin was also related to NF-
κB activation is not clear. In the herceptin-resistant SK-BR-
3-hr cells, the expression level of NF-κB increased in parallel
with the incremental dose of herceptin. When treated with
curcumin, the expression of NF-κBw a sd e c r e a s e d ,a c c o m -
panied with increased cell death. The ability of curcumin to
inhibit herceptin-resistant SK-BR-3 cells may be related to
the downregulation of HER-2 oncoprotein, and suppression
of related Akt, MAPK, and NF-κB signaling pathways. The
ability of curcumin to downregulate EGFR and HER-2
oncoproteins and inhibit the phosphorylation of Akt and
MAPK and NF-κB activation suggests that curcumin has
potential in the treatment of HER-2-overexpressed and/or
herceptin-resistant breast cancer.
The interaction of curcumin and herceptin in HER-2-
overexpressed cancer has rarely been reported. Whether the
combination of herceptin with curcumin had any therapeu-
tic advantage over herceptin alone is unknown. In the in
vitroBT-474celllinestudy,thecombinationofherceptinand
curcumin showed an advantage over either treatments alone
(Figure 3). The combination of herceptin and curcumin
exerted a biphasic interaction on the growth of BT-474 cells.
A synergistic eﬀect was present when a low dose of herceptin
(0.1–1μg/mL) was combined with curcumin, while a high
dose (>10μg/mL) of herceptin would exert an antagonistic
eﬀect when combined with curcumin (Table 1). In the SK-
BR-3-hr cells, the combination of herceptin with curcumin
exerted neither a synergistic nor antagonistic eﬀect. This
biphasic interaction observed in vitro warrants caution when
herceptin is to be used with curcumin or other medications.
In the xenograft animal study, curcumin treatment eﬀec-
tively reduced the tumor volume by 76.7%, compared with
the control; however, it was not as eﬀective as of herceptin,
whichachievedan86.7%tumorreduction(Figure 6(a)).The
combination of herceptin and curcumin showed a greater
antitumor eﬀect than curcumin alone (87.5% versus 76.7%
in tumor regression) but a similar eﬀe c tt ot h a to fh e r c e p t i n
(87.5% versus 86.7%). The anticipated synergistic eﬀect of
combining herceptin with curcumin was not observed in
our in vivo xenograft animal model. Although curcumin
might not interfere with herceptin in the normal physiologic
concentration, from our in vivo study, combined herceptin
and curcumin was not better than herceptin alone. More
solid evidence might be needed to support the rationale of
combing herceptin with curcumin in the treatment of HER-
2-overexpressed breast cancer.
It has been reported that curcumin could suppress taxol-
induced NF-κB, and curcumin combined with taxol showed
greater antitumor eﬀects than taxol alone [31, 33]. In our
in vivo xenograft study, the combination of curcumin and
taxol had therapeutic eﬀects comparable with taxol and
herceptin, one of the current preferred regimens for HER-2-
overexpressed breast cancer (Figure 6(b)). The combination
of taxol + herceptin + curcumin was associated with the
smallest mean tumor volume although this was not statis-
tically diﬀerent from that of the taxol and herceptin regimen.
Curcumin was rated safe and well-tolerated [45]; how-
ever, the application of curcumin might be limited by its
low bioavailability [16, 17, 45, 46]. To reduce the impact
of the low bioavailability of oral intake, we used an intra-
peritoneal injection to treat xenograft nude mice. In our
study, the body weight of herceptin and curcumin-treated
mice did not vary greatly during the entire treatment
period (Figure 6(c)), demonstrating the relative safety and
tolerability of curcumin as previously reported in animal
and human studies [16, 47, 48]. The main limitation of
our in vivo study was that we had only one ﬁxed dose
protocol for herceptin and/or curcumin treatment, and the
serum concentration of the drugs was unknown. The dose
of herceptin used here was in accordance with the current
practice guideline [26], while the dose of curcumin was
derived from a previous report [49]. The optimal dose of
curcumin for HER-2-overexpressed breast cancer is unclear
and needs to be determined for maximum therapeutic eﬀect.
In this study, we showed that curcumin could reduce
the cell viability of both HER-2-overexpressed herceptin-
sensitive BT-474 cells and herceptin-resistant SK-BR-3-hr
breast cancer cells. In the BT-474 xenograft model, though
not as much as herceptin, curcumin did eﬀectively decrease
the tumor size. The combination of curcumin with her-
ceptin was not better than herceptin alone; however, the
combination of taxol and curcumin had an antitumor eﬀect
comparable with taxol and herceptin. The results, both in
vitro and in vivo, suggested that curcumin has the treatment
potential for HER-2-overexpressed breast cancer.
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